BTG Pharmaceuticals
Michelle Barnard has extensive work experience in the pharmaceutical industry. Michelle is currently a Senior Director at BTG Pharmaceuticals, where they lead the Market Access Strategy team. Prior to their current role, Michelle worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Director, focusing on Value Access & Pricing in the Immunology division. Before that, they held the position of Executive Director at Bayer Pharmaceuticals, overseeing Contract Analytics & Generation. Michelle also has a long history at Novartis, where they served as an Executive Director, managing Managed Markets, Pricing & Reimbursement for various therapeutic areas. Additionally, at Novartis, they were a Director, leading the Market Access, Pricing & Contracting Strategy team. Michelle began their pharmaceutical career at Bristol-Myers Squibb, where they held multiple roles, including Strategy and Portfolio Analysis for Global Marketing and Managed Markets, Pricing & Contracting Strategy. Overall, Michelle Barnard has a wealth of experience in market access, pricing, and contracting strategy within the pharmaceutical industry.
Michelle Barnard has a Master of Business Administration (M.B.A.) in Finance, General from Fairleigh Dickinson University-Florham Campus, starting in 1998.
This person is not in any offices
BTG Pharmaceuticals
1 followers
BTG is a dedicated ally to healthcare providers treating patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. Improving patients’ quality of life and offering hope is what motivates and inspires us. BTG was acquired by SERB Pharmaceuticals in 2020. SERB now operates in the US as BTG Pharmaceuticals.